Smita S. Chandran, Ph.D.
Affiliations: | 2009 | Molecular Microbiology and Immunology | University of Maryland School of Medicine, Baltimore, MD, United States |
Area:
ImmunologyGoogle:
"Smita Chandran"Parents
Sign in to add mentor| Donna L. Farber | grad student | 2009 | University of Maryland Medical School | |
| (TLR2 engagement primes for expansive effector and memory CD4 T cells through early effects on DC activation.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Yi F, Cohen T, Zimmerman N, et al. (2024) CAR-engineered lymphocyte persistence is governed by a FAS ligand/FAS auto-regulatory circuit. Biorxiv : the Preprint Server For Biology |
| Klebanoff CA, Chandran SS, Baker BM, et al. (2023) T cell receptor therapeutics: immunological targeting of the intracellular cancer proteome. Nature Reviews. Drug Discovery |
| Drakes DJ, Rafiq S, Purdon TJ, et al. (2020) Optimization of T-cell receptor-modified T cells for cancer therapy. Cancer Immunology Research |
| Gejman RS, Jones HF, Klatt MG, et al. (2020) Identification of the targets of T cell receptor therapeutic agents and cells by use of a high throughput genetic platform. Cancer Immunology Research |
| Chandran SS, Klebanoff CA. (2019) T cell receptor-based cancer immunotherapy: Emerging efficacy and pathways of resistance. Immunological Reviews. 290: 127-147 |
| Scott AC, Dündar F, Zumbo P, et al. (2019) TOX is a critical regulator of tumour-specific T cell differentiation. Nature |
| Chandran S, Ma J, Klatt MG, et al. (2019) Abstract CN01-03: T cell receptor gene therapy for a public neoantigen derived from mutated PIK3CA, a dominant driver oncogene in breast and endometrial cancers Molecular Cancer Therapeutics. 18 |
| Klebanoff CA, Crompton JG, Leonardi AJ, et al. (2017) Inhibition of AKT signaling uncouples T cell differentiation from expansion for receptor-engineered adoptive immunotherapy. Jci Insight. 2 |
| Chandran SS, Somerville RP, Yang JC, et al. (2017) Treatment of metastatic uveal melanoma with adoptive transfer of tumour-infiltrating lymphocytes: a single-centre, two-stage, single-arm, phase 2 study. The Lancet. Oncology |
| Rothermel LD, Sabesan A, Stephens DJ, et al. (2015) Identification of an immunogenic subset of metastatic uveal melanoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research |